Thursday 22 September
Please find below the programme schedule for Thursday 22 September 2022.
Meet the experts session 1
08:00
Suite No. 292 (Ruby) | M1.1 Diagnostic Rounds Interactive session for diagnosis of emerging and re-emerging fungal infections
Birgit Willinger, Austria and Jurgen Prattes, Germany
08:00
Suite No. 293 (Sapphire) | M1.2 Human Pythiosis
Ariya Chindamporn, Thailand and Rongpong Plongla, Thailand
08:00
Suite No. 294 (Emerald) |M1.3 Standardization of diagnostic mycology laboratories
Malcolm Richardson, UK and Amir Seyedmousavi, USA
09:00
Conference hall B | Key note (P3): Progress in fungal diagnostics: the pros and cons
Cornelia Lass Flörl, Austria
10:00
Break
Conference hall C - Exhibition
Parallel session 4
Parallel session 4 will take place from 10:30 AM -12:00 PM and consists of five symposia.
Conference hall B | S4.1 Treatment of Rare Mould Infections in 2021: The role of new and old antifungals
Chairs: Martin Hoenigl, Austria and Ritesh Agarwal, India
10:30
S4.1a Fusariosis: MICs, Mono versus CombinationTherapy and Fosmanogepix
Martin Hoenigl, Austria
10:50
S4.1b Lomentosporiosis: From Voriconazole/Terbinafine combination to Olorofim
Danila Seidel, Gemany
11:10
S4.1c Rasamsonia and Paecilomyces/Purpureocillium: Current state of the art and new treatment options
Rosanne Sprute, Germany
11:30
S4.1d* In vitro activity of eight antifungals against 3,343 filamentous pathogenic fungi collected during 18 years at the French National Reference Center for invasive Mycosis and Antifungals
Dea Garcia-Hermoso, France
11:45
Q&A with all speakers
Conference hall A | S4.2 Advances in Diagnosis of Invasive fungal infection
Chairs: Boualem Sendid, France and Bansidhar Tarai, India
10:30
S4.2a Advances in the diagnosis of invasive fungal infection: invasive candidiasis
Boualem Sendid, France
10:50
S4.2b Invasive aspergillosis
Katrien Lagrou, Belgium
11:10
S4.2c Invasive mucormycosis
Hariprasath Prakash, India
11:30
S4.2d* Efficacy of LD Bio Aspergillus ICT Lateral flow assay for serodiagnosis of chronic pulmonary aspergillosis
Animesh Ray, India
11:45
Q&A with all speakers
Suite No. 292 (Ruby) | S4.3 Emergent species of the Candida genus
Chairs: Neil Gow, UK and Niranjan Nayak, India
10:30
S4.3a Candida tropicalis - molecular mechanism of drug resistance and detection
Anup Ghosh, India
10:50
S4.3b Candida glabrata-host interaction
Sascha Brunke, Germany
11:10
S4.3c Candida glabrata, new tools to study stress, pathogenesis and drug resistance’
Jane Usher, UK
11:30
S4.3d* Mechanism of fluconazole resistance in Candida vulturna, a member of the Candida haemulonii complex of multidrug resistant yeasts
Guillermo Garcia Effron, Argentina
11:45
Q&A with all speakers
Suite No. 293 (Sapphire) | S4.4 International Histoplasmosis Advocacy group (IHAG)
Chairs: Beatriz Gomez, Colombia, Tom Chiller, USA and Diego Caceres, USA
10:30
S4.4a Global burden of histoplasmosis
Antoine Adenis, France
10:50
S4.4b Progress on iHAG “100 by 25”
Tom Chiller, USA
11:10
S4.4c Histoplasmosis outside the traditional endemic region
Rita Oladele, Nigeria
11:30
S4.4d* TBD
11:45
Q&A with all speakers
Suite No. 294 (Emerald) | S4.5 Mycetoma Clinical Trial on fosravuconazole treatment in eumycetoma– Top Line Results
Chair: Ed Zijlstra, Switzerland
10:30
S4.5a A randomized, double blind phase ii proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan – Top Line Results
Ahmed Hassan Fahal, Sudan
10:50
S4.5b A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan – PK results
Borna Nyaoke, Kenya
11:05
S4.5c Using serum beta-glucan measurements and sequencing of the Madurella mycetomatis azole target gene to predict therapeutic outcome during azole treatment in human mycetoma
Wendy van de Sande, Netherlands
11:20
S4.5d* Comparing the diagnostic performance of the commonly used eumycetoma diagnostic tests using sequencing of the internally transcribed spacer region as the golden standard
Emmanuel Edwar Siddig, Sudan
11:35
General discussion
12:00
Lunch and Poster session 2
Conference hall C - Exhibition
Conference hall B | Importance of Turn Around Time In Fungal Diagnostics
Sponsored sympsium by Biostate Inc.
13:00
Diagnostic gap in fungal infections
Dr Nandini Sethuraman
13:15
Serological diagnosis of fungal infections
Dr Bansidhar Tarai
13:30
Molecular and non-culture-based tests
Dr Pratibha Kale
13:45
Q&A and close
14:00
Conference hall B | Key note 4 (P4): COVID-19 associated fungal infections
Martin Hoenigl, Austria
Parallel session 5
Parallel session 5 will take place from 03:00 05:30 PM and consists of five symposia.
Conference hall B | S5.1 Antifungal Resistance
Chairs: Jacques Meis, Netherlands and Danila Seidel, Germany
15:00
S5.1a Candida Tropicalis: Increasing Resistance
Yee-Chun Chen, Taiwan
15:20
S5.1b Azole-resistance in Aspergillus fumigatus: Clinical implications in haematological patients
Danila Seidel, Germany
S5.1c Resistance in rare fungal infections
Ashutosh Singh, India
16:00
S5.1d* Mechanisms of azole antifungal resistance in clinical isolates of Candida tropicalis
Anup Ghosh, India
16:15
Q&A with all speakers
Conference hall A | S5.2 The threat of invasive fungal infections: the first WHO list of fungal pathogens of public health importance
Chairs: Arunaloke Chakrabarti, India and Daniel Marcano,WHO HQ
15:00
S5.2a Development of WHO priority pathogens list of public health importance
Justin Beardsley, Australia
15:20
S5.2b AMR fungal infections global burden: surveillance challenges, gap & opportunities: WHO GLASS pilot
Daniel Marcano,WHO HQ
15:40
S5.2c Current state of research and development of antifungals treatment and diagnostics
Orla Morrissey, Australia
16:00
Q&A with all speakers
Suite No. 292 (Ruby) | S5.3 Cellular pleomorphism and fungal virulence
Chairs: Rupinder Kaur, India and Dee Carter, Australia
15:00
S5.3a Unraveling the genetic determinants of virulence in Cryptococcus
Katrina Jackson, USA
15:20
S5.3b Fungal spores: Initiators of colonization and infection
Tim Baltussen, Netherlands
15:40
S5.3c Investigating the link between pleomorphism and virulence in Cryptococcus
Kenya Fernandes, Australia
16:00
S5.3d* TBD
16:15
Q&A with all speakers
Suite No. 293 (Sapphire) |S5.4 Free oral paper session
Chairs: Tanu Singhal, India and Gagandeep Singh, India
15:00
S5.4a* Main reservoirs of Trichophyton mentagrophytes Type V in Iran
Ali Rezaei-matehkolaei, Iran
15:20
S5.4b* Genomic variation structure in clinical isolate collections alters benefits of association screening: a study of Cryptococcus neoformans var. grubii in Colombia
Oliver Keatinge Clay, Colombia
15:40
S5.4c* TBD
16:00
S5.4d* Agrochemicals potentiate multidrug resistance and alter virulence in Cryptococcus neoformans via hitch-hiking effect of aneuploidy
Liuliu Sun, China
16:15
Q&A with all speakers
Suite No. 294 (Emerald) | S5.5 Genomic Epidemiology of Fungal Infections
Chairs: Nancy Chow, USA, Khuraijam Ranjana Devi, India and Nelesh Govender, South Africa
15:00
S5.5a Standing Up FungiNet: Genomic epidemiology and surveillance of fungal diseases
Nancy Chow, USA
15:20
S5.5b WGS typing for outbreak investigations
Alexandre Alanio, France
15:40
S5.5c Future of molecular typing in fungi
David Engelthaler, USA
16:00
S5.5d* Molecular epidemiology of Microsporum canis infection in Japan
Takashi Mochizuki, Japan
16:15
Q&A with all speakers
16:30
16:30
Break
Parallel session 6
Parallel session 6 will take place from 05:45 - 06:15 PM and consists of five symposia.
Conference Hall B | S6.1 Antifungal Prophylaxis in Children with Cancer and HSCT
Chair: Andreas Groll, Germany
16:45
S6.1a What do pediatric guidelines recommend?
Adilia Warris, UK
17:05
S6.1b Challenges in antifungal prophylaxis in the real life setting
Tanu Singhal, India
17:25
S6.1c Potential utility of extended dosing regimens
Andreas Groll, Germany
17:45
S6.1d* First case report of paediatric blood stream infection by Candida magnoliae in a known case of B cell ALL post induction chemotherapy in Central India
Subhasish Bhadra, India
18:00
Q&A with all speakers
Conference hall A | S6.2 Resurgence of dermatophytic infections
Chairs: Rosalie Sacheli, Belgium and Shivaprakas Rudramurthy, India
16:45
S6.2a The Indian epidemic: clinical and epidemiologic aspects
Shyam Verma, India
17:05
S6.2b In vitro susceptibility testing of dermatophytes: towards standardisation
Ditte Saunte, Denmark
17:25
S6.2c Dermatophyte antifungal resistance
Eric Dannaoui, France
17:45
S6.2d* Dermatophytosis due to Trichophyton erinacei caused by contact with african hedgehogs as family pets
Alexandro Bonifaz, Mexico
18:00
Q&A with all speakers
Suite No. 293 (Sapphire) | S6.4 One health approach for endemic mycoes in the Americas
Chairs: Flavio Queiroz-Telles, Brazil and Arnaldo Lopes Colombo, Brazil
16:45
S6.4a Chromoblastomycosis as occupational disease
Daniel Wagner, Brazil
17:00
S6.4b Sporotrichosis in pediatric patients
Flavio Queiroz-Telles, Brazil
17:15
S6.4c Primary cutaneous implantation coccidioidomycosis
Alexandro Bonifaz, Mexico
17:30
S6.d Coccidioidomycosis & climate change
Tom Chiller, USA
17:45
S6.4e Discovering new histoplasmosis patients in LATAM
Diego Caceres, USA
18:00
Q&A with all speakers
Suite No. 294 (Emmerald) | S6.5 Efforts of improving the management of mycetoma: working towards the 2030 goals
Chairs: Wendy van de Sande, Netherlands and Ahmed Hassan Fahal, Sudan
16:45
S6.5a Metagenomic analysis of Sennar and White Nile states in Sudan to identify mycetoma causative agents in the surroundings
Sahar Bakhiet, Sudan
17:05
S6.5b Genomics and metagenomics of Madurella mycetomatis
Nancy Chow, USA
17:25
S6.5c MycetOS: identifying drugs which can penetrate the mycetoma grain
Wendy van de Sande, Netherlands
17:45
S6.5d* Molecular identification of mycetoma causative agents from patients in hospital setting in Senegal
Doudou Sow, Senegal
18:00
Q&A with all speakers
18:15
Conference hall B | Key note (P5): Advances in the field of aspergillosis
Paul Verweij, Netherlands
19:00
Young ISHAM dinner and party
Banquet Hall (3rd floor Ashok Hotel) - only for pre registered participants